DE69328430T2 - Zielgerichte liposome zur blut-hirne schranke - Google Patents

Zielgerichte liposome zur blut-hirne schranke

Info

Publication number
DE69328430T2
DE69328430T2 DE69328430T DE69328430T DE69328430T2 DE 69328430 T2 DE69328430 T2 DE 69328430T2 DE 69328430 T DE69328430 T DE 69328430T DE 69328430 T DE69328430 T DE 69328430T DE 69328430 T2 DE69328430 T2 DE 69328430T2
Authority
DE
Germany
Prior art keywords
receptors
blood brain
targeted
targeted liposome
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69328430T
Other languages
English (en)
Other versions
DE69328430D1 (de
Inventor
Michael J Micklus
Nigel H Greig
Stanley I Rapoport
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
National Institutes of Health NIH
Original Assignee
US Department of Health and Human Services
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, National Institutes of Health NIH filed Critical US Department of Health and Human Services
Publication of DE69328430D1 publication Critical patent/DE69328430D1/de
Application granted granted Critical
Publication of DE69328430T2 publication Critical patent/DE69328430T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
DE69328430T 1992-07-27 1993-07-23 Zielgerichte liposome zur blut-hirne schranke Expired - Fee Related DE69328430T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92119992A 1992-07-27 1992-07-27
PCT/US1993/006942 WO1994002178A1 (en) 1992-07-27 1993-07-23 Targeting of liposomes to the blood-brain barrier

Publications (2)

Publication Number Publication Date
DE69328430D1 DE69328430D1 (de) 2000-05-25
DE69328430T2 true DE69328430T2 (de) 2001-01-25

Family

ID=25445079

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69328430T Expired - Fee Related DE69328430T2 (de) 1992-07-27 1993-07-23 Zielgerichte liposome zur blut-hirne schranke

Country Status (8)

Country Link
US (1) US20020025313A1 (de)
EP (1) EP0652775B1 (de)
JP (1) JPH07509250A (de)
AT (1) ATE191853T1 (de)
AU (1) AU677216B2 (de)
CA (1) CA2141216A1 (de)
DE (1) DE69328430T2 (de)
WO (1) WO1994002178A1 (de)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
AU5135396A (en) * 1995-02-28 1996-09-18 Nature Technology Corporation Biosynthetic virus vectors for gene therapy
WO1997028817A1 (en) * 1996-02-09 1997-08-14 Cheng Pi Wan Receptor ligand-facilitated delivery of biologically active molecules
AU6443298A (en) 1997-02-28 1998-09-18 Nature Technology Corporation Self-assembling genes, vectors and uses thereof
WO1999000150A2 (en) * 1997-06-27 1999-01-07 Regents Of The University Of California Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
CA2481020A1 (en) * 2001-09-28 2003-04-03 Saoirse Corporation Localized non-invasive biological modulation system
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
CA2481334A1 (en) * 2002-04-01 2003-10-16 Anthony C. Stevens Tissue-specific endothelial membrane proteins
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
US20070065497A1 (en) * 2005-09-20 2007-03-22 Guilford Frederick T Combination and method using EDTA combined with glutathione in the reduced state encapsulated in a liposome to facilitate the method of delivery of the combination as an oral, topical, intraoral or transmucosal, for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy
US20050142141A1 (en) * 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
EP1620564A4 (de) * 2003-04-18 2008-03-12 Cytovia Inc Verfahren zur behandlung von auf apoptoseinduktion reagierenden krankheiten und screening-tests
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
ATE514783T1 (de) 2003-11-12 2011-07-15 Schering Corp Plasmidsystem zur expression mehrerer gene
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
US20050244400A1 (en) 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US8349359B2 (en) * 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
DE602005025685D1 (de) * 2004-12-03 2011-02-10 Schering Corp Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie
CA2592320C (en) 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
NZ561648A (en) * 2005-04-15 2009-11-27 Schering Corp Methods and composition of IGF1R inhibitors for treating or preventing cancer
WO2006126208A2 (en) * 2005-05-26 2006-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
US20060286103A1 (en) * 2005-06-15 2006-12-21 Parag Kolhe Stable antibody formulation
CN103396485B (zh) 2005-12-15 2016-08-10 健泰科生物技术公司 靶向多聚泛蛋白的方法和组合物
SG173385A1 (en) 2006-07-14 2011-08-29 Ac Immune S A Ch Humanized antibody against amyloid beta
MY165105A (en) 2006-07-14 2018-02-28 Ac Immune Sa Humanized antibody against amyloid beta
LT3851447T (lt) 2006-10-12 2023-12-27 Bellus Health Inc. Metodai, junginiai, kompozicijos ir transporteriai, skirti 3- amino-1- propansulfonrūgšties pristatymui
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
JP2010530744A (ja) 2007-06-12 2010-09-16 エーシー イミューン ソシエテ アノニム アミロイドβに対するヒト化抗体
CA2690434C (en) 2007-06-12 2018-05-22 Ac Immune S.A. Monoclonal anti beta amyloid antibody
US20090047318A1 (en) * 2007-08-16 2009-02-19 Abbott Cardiovascular Systems Inc. Nanoparticle-coated medical devices and formulations for treating vascular disease
CN101998863B (zh) 2007-10-05 2015-09-16 基因技术公司 抗淀粉状蛋白β抗体在眼病中的用途
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
CA2723412A1 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
WO2010009271A2 (en) 2008-07-15 2010-01-21 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
EP2342356A4 (de) 2008-09-29 2012-11-21 Univ Ben Gurion Amyloid-beta-peptidasen und verwendungsverfahren dafür
TWI572357B (zh) 2008-10-14 2017-03-01 建南德克公司 免疫球蛋白變異體及其用途
WO2010048446A2 (en) 2008-10-22 2010-04-29 Genentech, Inc. Modulation of axon degeneration
JP6039183B2 (ja) 2008-12-23 2016-12-07 ジェネンテック, インコーポレイテッド プロテインaに対する結合が変化した免疫グロブリン変異体
WO2011005098A1 (en) 2009-07-10 2011-01-13 Abbott Healthcare Products B.V. Peptide ligands for targeting to the blood-brain barrier
ES2599076T3 (es) 2009-09-02 2017-01-31 Genentech, Inc. Smoothened mutante y métodos de utilización del mismo
CN104043126A (zh) 2009-10-22 2014-09-17 霍夫曼-拉罗奇有限公司 轴突变性的调节
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
JP5818805B2 (ja) 2009-12-11 2015-11-18 ジェネンテック, インコーポレイテッド 抗vegf−c抗体及びその使用方法
US8901129B2 (en) 2009-12-11 2014-12-02 Genecode As Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
WO2011079185A1 (en) 2009-12-23 2011-06-30 Genentech, Inc. Anti-bv8 antibodies and uses thereof
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
DK2568976T3 (en) 2010-05-10 2016-01-11 Academia Sinica Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses
NZ606357A (en) 2010-07-30 2015-05-29 Genentech Inc Safe and functional humanized anti beta-amyloid antibody
EP3527220A1 (de) 2010-08-12 2019-08-21 AC Immune S.A. Manipulation von impfstoffen
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
US9304138B2 (en) 2010-10-07 2016-04-05 Katholieke Universiteit Leuven Pharmaceutical composition
TW201223561A (en) 2010-10-26 2012-06-16 Ac Immune Sa Preparation of an antigenic construct
WO2012064836A1 (en) 2010-11-10 2012-05-18 Genentech, Inc. Methods and compositions for neural disease immunotherapy
LT2646470T (lt) 2010-11-30 2017-06-12 F. Hoffmann-La Roche Ag Mažo giminingumo antitransferino receptorių antikūnai ir jų panaudojimas pernešti gydomąjį vienos grandinės antikūną (scfv) per hematoencefalinį barjerą
WO2012118376A1 (en) 2011-03-01 2012-09-07 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances
US8629114B2 (en) 2011-06-03 2014-01-14 Ophidion Inc. Compositions and methods for transport across the blood brain barrier
US20140161896A1 (en) * 2011-08-04 2014-06-12 Ramot At Tel-Aviv University Ltd. Particles for the treatment of neurodegenerative diseases
KR101981351B1 (ko) 2011-10-07 2019-09-02 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
EP2766028B1 (de) 2011-10-14 2017-08-16 F. Hoffmann-La Roche AG Peptidinhibitoren von bace1
JP6338530B2 (ja) 2011-11-10 2018-06-06 ジェネンテック, インコーポレイテッド アルツハイマー病を治療、診断、および監視するための方法
CN104520322B (zh) 2012-04-05 2019-11-15 Ac免疫有限公司 人源化tau抗体
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
SG11201407669QA (en) 2012-05-21 2014-12-30 Genentech Inc Methods for improving safety of blood-brain barrier transport
CA2871695A1 (en) 2012-05-22 2013-11-28 F. Hoffmann-La Roche Ag Substituted dipyridylamines and uses thereof
CN104718188B (zh) 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
WO2014008458A2 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
AU2013305827A1 (en) 2012-08-21 2015-03-05 Academia Sinica Benzocyclooctyne compounds and uses thereof
BR112015006737A2 (pt) 2012-09-27 2017-07-04 Hoffmann La Roche compostos de sulfonamida substituídos
AU2013204200B2 (en) 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
MX2015009270A (es) 2013-01-18 2015-10-30 Hoffmann La Roche Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP2968280A4 (de) 2013-03-14 2016-08-10 Genentech Inc Substituierte triazolopyridine und verfahren zur verwendung davon
RU2661111C2 (ru) 2013-03-15 2018-07-11 Ац Иммуне С.А. Антитела к тау и способы применения
RU2015147601A (ru) 2013-05-01 2017-06-05 Ф. Хоффманн-Ля Рош Аг С-связанные гетероциклоалкилзамещенные пиримидины и их применения
MX2015015130A (es) 2013-05-01 2016-02-18 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos.
KR102293064B1 (ko) 2013-05-20 2021-08-23 제넨테크, 인크. 항-트랜스페린 수용체 항체 및 사용 방법
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
EP3038600B1 (de) 2013-08-27 2020-06-03 Northeastern University System zur freisetzung von wirkstoffen in nanopartikelform und verfahren zur behandlung von krebs und neurotraumata
AU2014317889B2 (en) 2013-09-06 2020-03-05 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
TWI657076B (zh) 2013-10-11 2019-04-21 赫孚孟拉羅股份公司 經取代磺醯胺化合物
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
WO2015100269A2 (en) * 2013-12-27 2015-07-02 Double Helix Corporation Compositions and methods for providing active telomerase to cells in vivo
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
US9982041B2 (en) 2014-01-16 2018-05-29 Academia Sinica Compositions and methods for treatment and detection of cancers
US20170044232A1 (en) 2014-02-04 2017-02-16 Genentech, Inc. Mutant smoothened and methods of using the same
TWI797430B (zh) 2014-03-27 2023-04-01 中央研究院 反應性標記化合物及其用途
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US11319567B2 (en) 2014-05-27 2022-05-03 Academia Sinica Fucosidase from bacteroides and methods using the same
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
WO2015184004A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
WO2015184001A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
EP3166939B1 (de) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutische verbindungen und verfahren zur verwendung davon
CA2960712A1 (en) 2014-09-08 2016-03-17 Academia Sinica Human inkt cell activation using glycolipids
WO2016081640A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
CA2966964A1 (en) 2014-11-19 2016-05-26 Michal Novak Humanized tau antibodies in alzheimer's disease
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
EP3845565A3 (de) 2014-11-19 2021-09-08 Genentech, Inc. Antikörper gegen bace1 und verwendung davon zur immuntherapie bei neuronalen erkrankungen
BR112017011234A2 (pt) 2014-12-10 2018-03-27 Genentech Inc anticorpos contra receptor da barreira hematoencefálica e métodos de uso
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
CN107430127B (zh) 2015-01-24 2020-08-28 中央研究院 癌症标记及其使用方法
CA2972072A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
JP6942633B2 (ja) 2015-01-30 2021-09-29 アカデミア シニカAcademia Sinica 抗体の増強された有効性のための普遍的グリコフォームに関する組成物および方法
CA2975875A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
WO2016142310A1 (en) 2015-03-09 2016-09-15 F. Hoffmann-La Roche Ag Tricyclic dlk inhibitors and uses thereof
CN107835805A (zh) 2015-05-22 2018-03-23 基因泰克公司 被取代的苯甲酰胺和其使用方法
CR20170562A (es) 2015-06-24 2018-02-01 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad diseñada.
WO2017035271A1 (en) 2015-08-27 2017-03-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2017041027A1 (en) 2015-09-04 2017-03-09 Obi Pharma, Inc. Glycan arrays and method of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CA2997801A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
US10899732B2 (en) 2015-11-25 2021-01-26 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
JP2019509721A (ja) 2016-02-04 2019-04-11 キュリス,インコーポレイテッド 突然変異体スムースンド及びその使用方法
CN109195996A (zh) 2016-03-08 2019-01-11 中央研究院 N-聚醣及其阵列的模组化合成方法
CN109311995A (zh) 2016-03-29 2019-02-05 台湾浩鼎生技股份有限公司 抗体、药物组合物和方法
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
JP2019513714A (ja) 2016-03-30 2019-05-30 ジェネンテック, インコーポレイテッド 置換ベンズアミド及びその使用方法
TWI697333B (zh) 2016-04-22 2020-07-01 台灣浩鼎生技股份有限公司 經由Globo系列抗原之免疫活化或免疫調節之癌症免疫療法
JP7043483B2 (ja) 2016-07-20 2022-03-29 エフ.ホフマン-ラ ロシュ アーゲー 二環式プロリン化合物
CN109476628B (zh) 2016-07-20 2022-01-11 豪夫迈·罗氏有限公司 作为trpa1调节剂的磺酰基环烷基酰胺化合物
CA3032049C (en) 2016-07-27 2023-11-07 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
CN110062767B (zh) 2016-07-29 2023-07-11 台湾浩鼎生技股份有限公司 人抗体、药物组合物和方法
WO2018029288A1 (en) 2016-08-12 2018-02-15 F. Hoffmann-La Roche Ag Sulfonyl pyridyl trp inhibitors
JP7213549B2 (ja) 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド 抗体、結合性断片、および使用の方法
EP3526219B1 (de) 2016-10-17 2021-12-15 F. Hoffmann-La Roche AG Bicyclische pyridonlactame und verfahren zur verwendung davon
US11000601B2 (en) 2016-11-21 2021-05-11 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
JP7171567B2 (ja) 2016-11-28 2022-11-15 エフ.ホフマン-ラ ロシュ アーゲー 一過性受容体電位型チャネル阻害剤としてのオキサジアゾロン類
CN110023313B (zh) 2016-12-02 2022-10-25 豪夫迈·罗氏有限公司 二环酰胺化合物及其使用方法
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
CN114874209A (zh) 2017-03-07 2022-08-09 豪夫迈·罗氏有限公司 噁二唑瞬时受体电位通道抑制剂
WO2018175707A1 (en) 2017-03-24 2018-09-27 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
CN108939089B (zh) * 2017-05-17 2021-11-02 复旦大学 群体感应多肽及其在制备肿瘤靶向诊治递药系统中的用途
CN110997693A (zh) 2017-06-07 2020-04-10 阿德克斯公司 τ聚集抑制剂
TWI805595B (zh) 2017-07-14 2023-06-21 瑞士商赫孚孟拉羅股份公司 二環酮化合物及其使用方法
EP3668886A2 (de) 2017-08-18 2020-06-24 Adrx, Inc. Peptidinhibitoren der tau-aggregation
JP7362600B2 (ja) 2017-10-11 2023-10-17 エフ. ホフマン-ラ ロシュ アーゲー Rip1キナーゼ阻害剤として使用するための二環式化合物
EP3704145A1 (de) 2017-10-30 2020-09-09 F. Hoffmann-La Roche AG Verfahren zur in-vivo-erzeugung multispezifischer antikörper aus monospezifischen antikörpern
MX2020003451A (es) 2017-10-31 2020-08-03 Hoffmann La Roche Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos.
AU2018374682B2 (en) 2017-11-30 2021-12-16 Hanmi Pharm. Co., Ltd. Salts of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno(3,2-d)pyrimidine-7-carboxamide, and crystalline forms thereof
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
WO2019164778A1 (en) 2018-02-20 2019-08-29 Genentech, Inc. Process for preparing 1-arylsulfonyl-pyrrolidine-2-carboxamide transient receptor potential channel antagonist compounds and crystalline forms thereof
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
CA3095443A1 (en) 2018-03-28 2019-10-03 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
JP2021519788A (ja) 2018-03-30 2021-08-12 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物
EP3781571B1 (de) 2018-04-20 2024-01-17 F. Hoffmann-La Roche AG N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-2-carboxamid-derivate und ähnliche verbindungen als rip1 kinase inhibitoren zur behandlung von z.b. reizdarmsyndrom (rds)
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
TW202035444A (zh) 2018-06-27 2020-10-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
TW202024023A (zh) 2018-09-03 2020-07-01 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
JP2022514290A (ja) 2018-12-20 2022-02-10 ジェネンテック, インコーポレイテッド 改変抗体fcおよび使用方法
AR119673A1 (es) 2019-01-11 2022-01-05 Hoffmann La Roche Compuestos bicíclicos de cetona y métodos para utilizarlos
EP3946269A4 (de) * 2019-03-27 2023-05-03 University of Georgia Research Foundation, Inc. Verfahren zur herstellung gezielter vesikel und so hergestellte zusammensetzungen
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
WO2021097110A1 (en) 2019-11-13 2021-05-20 Genentech, Inc. Therapeutic compounds and methods of use
EP4069734A1 (de) 2019-12-04 2022-10-12 AC Immune SA Neuartige moleküle zur therapie und diagnose
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
WO2022034228A1 (en) 2020-08-14 2022-02-17 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
CN116744933A (zh) 2020-10-02 2023-09-12 基因泰克公司 用于制备双杂芳基化合物及其晶型的方法
WO2022079297A1 (en) 2020-10-16 2022-04-21 Ac Immune Sa Antibodies binding to alpha-synuclein for therapy and diagnosis
WO2023028056A1 (en) 2021-08-24 2023-03-02 Genentech, Inc. 3-amino piperidyl sodium channel inhibitors
WO2023028077A1 (en) 2021-08-24 2023-03-02 Genentech, Inc. Sodium channel inhibitors and methods of designing same
US20230202984A1 (en) 2021-11-24 2023-06-29 Genentech, Inc. Therapeutic compounds and methods of use
TW202340212A (zh) 2021-11-24 2023-10-16 美商建南德克公司 治療性化合物及其使用方法
WO2023156549A1 (en) 2022-02-16 2023-08-24 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
WO2023194565A1 (en) 2022-04-08 2023-10-12 Ac Immune Sa Anti-tdp-43 binding molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
CA2025907A1 (en) * 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
AU8007791A (en) * 1990-06-15 1992-01-07 Cytel Corporation Intercellular adhesion mediators
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
JPH07509444A (ja) * 1991-11-26 1995-10-19 アルカーメス・インコーポレーテツド トランスフェリンセレプター特異的抗体−神経薬又は診断薬複合体の製造法

Also Published As

Publication number Publication date
WO1994002178A1 (en) 1994-02-03
EP0652775A1 (de) 1995-05-17
ATE191853T1 (de) 2000-05-15
JPH07509250A (ja) 1995-10-12
CA2141216A1 (en) 1994-02-03
DE69328430D1 (de) 2000-05-25
AU677216B2 (en) 1997-04-17
AU4687593A (en) 1994-02-14
US20020025313A1 (en) 2002-02-28
EP0652775B1 (de) 2000-04-19

Similar Documents

Publication Publication Date Title
DE69328430D1 (de) Zielgerichte liposome zur blut-hirne schranke
JP6817492B2 (ja) 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体
WO2004050016A3 (en) Delivery of pharmaceutical agents via the human insulin receptor
RU2628089C2 (ru) Комбинированная терапия иммуноцитокинами
WO2007097934A3 (en) Methods and compositions for using erythrocytes as carriers for delivery of drugs
Cusack Jr et al. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model
WO2005021579A3 (en) Epo mimetic peptides and fusion proteins
ATE207738T1 (de) Verfahren zur baladung von lipidvesikeln
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
EA199700197A1 (ru) Стабильные белково-фосфолипидные составы и способы их получения
HK1097449A1 (en) Methods for in vivo delivery of biologics and compositions useful therefor
DE69334266D1 (de) Therapeutische Zusammensetzungen aus Antikorper und Antisens Nukleinsäuren gegen Serrate
ZA200200789B (en) Multiple cytokine-antibody complexes.
GB2340121B (en) Delivery system
BRPI0406605B8 (pt) conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
MXPA04003569A (es) Mezclas bifasicas de glp-1 e insulina.
CN105294859A (zh) 脂蛋白复合物及其制备和用途
WO2002072636A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
ATE322255T1 (de) Polyamid-oligomere
US7147849B2 (en) Pharmaceutical formulation
MXPA03011499A (es) Proteinas de fusion de fce para el tratamiento de alergia y asma.
AU4363199A (en) Use of hmg proteins for the preparation of medicaments having cytotoxic activity
WO2002058589A3 (en) Agents and methods for promoting bone growth
Chène p53 as a drug target in cancer therapy

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: EFFERT UND KOLLEGEN, 12487 BERLIN

8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: WABLAT-LANGE-KARTHAUS, 14129 BERLIN

8339 Ceased/non-payment of the annual fee